Abstract: A method for at least partial deacetylation of a biopolymer comprising acetyl groups, including: a1) providing a biopolymer including acetyl groups; a2) reacting the biopolymer including acetyl groups with hydroxylamine (NH2OH) or a salt thereof at a temperature of 100° C. or less for 2-200 hours to form an at least partially deacetylated biopolymer; and a3) recovering the at least partially deacetylated biopolymer.
Abstract: A glycosaminoglycan derivative which is obtainable by a process that includes the steps of N-desulfation of from 25% to 100% of the N-sulfated residues of a glycosaminoglycan, and oxidation, by periodate at a pH of from 5.5 to 10.0, of from 25% to 100% of the 2-N-, 3-O-non-sulfated glucosamine residues, and of the 2-O-non-sulfated uronic acid residues of said glycosaminoglycan, under conditions effective to convert adjacent diols and adjacent OH/NH2 to aldehydes. The process further includes reduction, by sodium borohydride, of said oxidized glycosaminoglycan, under conditions effective to convert said aldehydes to alcohols, where the glycosaminoglycan is heparin, low molecular weight heparin, heparan sulfate or fractions thereof.
Abstract: A galactooligosaccharide composition comprising a mixture of disaccharides, trisaccharides, a tetrasaccharide and a pentasaccharide for use in preventing or treating cognitive dysfunction and/or emotional disturbances in neuropsychiatric illnesses or ageing.
Abstract: The disclosure provides an oral antiviral supplement composition comprising a lysine, an ascorbic compound, a flavonoid glycoside, a threonine, and a pyridoxine. The disclosure also provides a method of reducing viral replication in a cell comprising treating a virus-infected cell with a composition of the disclosure. The disclosure further provides a method for the treatment and prophylaxis of a viral infection in a patient comprising administering a composition of the disclosure.
Type:
Grant
Filed:
September 25, 2019
Date of Patent:
January 18, 2022
Assignee:
Vymedic, LLC
Inventors:
Kenneth E. Phillips, Cynthia A. Winning
Abstract: The present invention relates to preventing and/or treating urologic diseases and symptoms in humans or domestic animals. The present invention relates also to preventing and/or treating pain in the pelvic area. The invention relates to use of a heteropolysaccharide composition isolated from ligneous plants and comprising hemicelluloses, mainly glucomannans, but also xylans and pectic polysaccharides, as well as fractions, subgroups or mixtures of these, as pharmaceutical preparations, food additives and food products.
Type:
Grant
Filed:
September 7, 2017
Date of Patent:
January 18, 2022
Assignee:
MONTINUTRA LTD
Inventors:
Yvonne Konkol, Jenni Bernoulli, Bjarne Holmbom, Heikki Vuorikoski, Andrey Pranovich, Jussi Halleen
Abstract: Mithramycin side chain carboxylic acid (MTM-SA) derivative are provided, which include a substituted amino acid derivative, a substituted amino acid dipeptide derivative, or an unsubstituted dipeptide derivative. The MTM-SA derivatives are useful for treatment of cancer or neuro-diseases associated with an aberrant erythroblast transformation-specific transcription factor. Unique MTM-SA derivatives have increased selectively toward ETS transcription factor.
Type:
Grant
Filed:
September 5, 2018
Date of Patent:
January 18, 2022
Assignee:
University of Kentucky Research Foundation
Abstract: The present invention relates to a combination of ivermectin and brimonidine for use in the treatment and/or the prevention of moderate to severe rosacea, preferably by topical administration of a 1% ivermectin cream and 0.33% brimonidine gel.
Type:
Grant
Filed:
November 17, 2016
Date of Patent:
January 4, 2022
Assignee:
GALDERMA HOLDING SA
Inventors:
Philippe Martel, Nabil Kerrouche, Fabien Audibert
Abstract: The present invention relates to cannabinoid glycoside prodrugs suitable for site- and tissue-specific delivery of cannabinoid molecules. The present invention also relates to methods of forming the cannabinoid glycoside prodrugs through glycosyltransferase mediated glycosylation of cannabinoid molecules.
Type:
Grant
Filed:
September 22, 2016
Date of Patent:
December 28, 2021
Assignee:
Graphium Biosciences, Inc.
Inventors:
Brandon J. Zipp, Janee M. Hardman, Robert T. Brooke
Abstract: The present invention relates to a process for depleting epoxide species in epoxy-crosslinked polysaccharide gel compositions. In addition, the present invention relates to crosslinked polysaccharide gel compositions made by said process and their use in cosmetic and therapeutic applications.
Abstract: The present invention relates to the use of silthiofam for the treatment of soybean rust and agricultural compositions thereof. The invention further relates to a method of controlling, preventing and/or treating of phytopathogenic fungi causing soybean rust.
Abstract: The present invention discloses pharmaceutical compositions comprising ester derivatives of hyaluronic acid for use as a topical treatment in disorders of the vaginal mucosa characterised by loss of elasticity and hydration, such as vaginal dryness and/or atrophic vaginitis; said compositions can also be used successfully to lubricate the genital mucosa.
Type:
Grant
Filed:
October 4, 2019
Date of Patent:
December 14, 2021
Assignee:
FIDIA FARMACEUTICI S.p.A.
Inventors:
Laura Pilotto, Giovanni Gennari, Anna Maria Zanellato
Abstract: A method of preparing a hydrogel product comprising crosslinked glycosaminoglycan molecules, said method including: i) providing a glycosaminoglycan crosslinked by amide bonds, wherein the crosslinked glycosaminoglycans include ester crosslinks formed as byproducts during the amide crosslinking; and ii) subjecting the crosslinked glycosaminoglycans to alkaline treatment to hydrolyze ester crosslinks formed as byproducts during the amide crosslinking.
Abstract: The present invention relates to the use of cyanoglucoside according to formula (I) and formulations thereof in the prevention and/or treatment of diabetes and/or metabolic syndrome; wherein R1, R2 and R3 are independently selected from an optionally substituted mono- or di-saccharide, —O—R4, —O—C(O)—R4 and halogen, such as Cl, F or Br, wherein R4 is selected from H, alkyl, such as methyl, as well as tautomers, geometrical isomers, optically active forms, pharmaceutically acceptable salts and pharmaceutically active derivative thereof.
Type:
Grant
Filed:
June 28, 2016
Date of Patent:
November 23, 2021
Assignees:
UNIVERSITÉ DE GENÈVE, UNIVERSIDADE ESTADUAL PAULISTA JÚLIO DE MESQUITA FILHO
Inventors:
Luiz Leonardo Saldanha, Anne Ligia Dokkedal Bosqueiro, Jose Roberto Bosqueiro, Nathalia Aparecida De Paula Camaforte Henriques, Priscilla Maria Ponce Vareda, Wagner Vilegas, Emerson Ferreira Queiroz, Laurence Marcourt, Jean-Luc Wolfender
Abstract: The present invention relates to compositions, particularly compositions useful in maintaining and supporting healthy microflora in the female urogenital tract which could lead to inhibition of vaginal infections, as well as methods of treating and preventing vaginal infections. Compositions useful in supporting healthy microflora, disclosed herein, generally comprise a therapeutic amount of a first saccharide and a therapeutic amount of a second saccharide or an organic acid. The saccharides may be, for example, a pentose, a disaccharide, a cyclodextrin, a pectic substance or a non-digestible polysaccharide. The organic acid may be, for example, malic acid.
Type:
Grant
Filed:
September 29, 2015
Date of Patent:
November 9, 2021
Assignee:
Kimberly-Clark Worldwide, Inc.
Inventors:
Jingru Li, Lindsay Adrienne Peed, Cheryce Francina Joyner, Rebecca Ann Vongsa, David William Koenig, Ryan Daniel Bartell, Paige Nicole Hollmaier
Abstract: The present invention relates to use of a composition for maintenance of bone and/or cartilage health or prevention, alleviation and/or treatment of bone and/or cartilage disorders.
Type:
Grant
Filed:
May 8, 2020
Date of Patent:
November 9, 2021
Assignee:
Societe des Produits Nestle S.A.
Inventors:
Marie Noelle Horcajada, Fanny Membrez, Elizabeth Offord Cavin
Abstract: Nicotinamide ribose has many applications, including as a dietary supplement. This invention convers a process to prepare nicotinamide ribose it in its phosphorylated form. The instant invention is based on the discovery that nicotinamide ribose phosphate emerges in stable form by direct reaction of ribose-1,2-cyclic phosphate. It is based on the further conversion of the phosphorylated nicotinamide ribose product to unphosphorylated nicotinamide ribose upon treatment with an enzymatic phosphatase, most preferably in buffer containing borate. It is based on the further discovery that compositions of nicotinamide ribose with borate slow the decomposition of nicotinamide ribose, and therefore is more useful than compositions of nicotinamide ribose without borate.
Type:
Grant
Filed:
October 15, 2018
Date of Patent:
November 9, 2021
Inventors:
Hyo-Joong Kim, Steven A Benner, Ion Mircesti Scorei
Abstract: A nobiletin composition having high water solubility and a method for easily producing the same are provided. A method for producing a solid dispersion comprising nobiletin, comprising the step of mixing nobiletin or a nobiletin-containing product with a water-soluble hesperidin derivative, and then melting the mixture by heating; and the step of solidifying the melted product by cooling. A nobiletin-containing composition produced by the method.
Abstract: A process is described for preparing a stable emulsion that includes at least one avermectin. Also described, is the emulsion thus obtained, especially for use in the treatment of dermatological disorders such as rosacea.
Type:
Grant
Filed:
October 13, 2016
Date of Patent:
October 26, 2021
Assignee:
Galderma Holding SA
Inventors:
Claire Mallard, Richard Dugat, Elodie Roger, Ricardo Diaz
Abstract: Disclosed herein are new C-mannoside compounds and compositions and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in a human subject are also provided for the treatment diseases such as urinary tract infection.
Type:
Grant
Filed:
October 6, 2020
Date of Patent:
September 7, 2021
Assignees:
GlaxoSmithKline Intellectual Property Development Limited, Fimbrion Therapeutics, Inc.
Inventors:
Michael Joseph Bishop, Eugene L. Stewart, Katherine Louisa Widdowson, James Walter Janetka, Laurel Kathryn McGrane
Abstract: Disclosed is a skin preparation composition for external use containing complex hyaluronic acid as an active ingredient, and specifically relates to a skin preparation composition for external use that contains hyaluronic acid, sodium hyaluronate, and hydrolyzed hyaluronic acid as active ingredients, and are excellent in an active oxygen scavenging effect, a wrinkle improvement effect, a moisturizing effect, a skin irritation relief effect, an acne prevention effect, an atopy improvement effect, and an anti-inflammatory effect, an hair damage prevention effect, and a hair loss prevention and hair growth effect.
Type:
Grant
Filed:
January 9, 2020
Date of Patent:
September 7, 2021
Assignees:
J2KBIO CO., LTD., COSMECCA KOREA CO., LTD.
Inventors:
Jae Soeb Lee, Jun Tae Bae, Seok Jong Kim, Young Kwon Cha, Hang Eui Cho, Ju Tae Jeong, Kyeong Seok So